| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4750 | Sjf-1521 | Novel selective EGFR degrader |
|
| DCC4751 | Sjf-1528 | Novel potent EGFR degrader, being capable of penetrating the cell membrane, also degrading an exon-20 insertion mutant form of EGFR (ASV duplication) |
|
| DCC4752 | Sjg-136 | Novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity |
|
| DCC4753 | Sjp-l-5 | Novel inhibitor of HIV-1 infection by blocking viral DNA nuclear entry |
|
| DCC4754 | Sk-575 | Highly potent and efficacious proteolysis targeting chimera (PROTAC) degrader of PARP1 for treating cancers, potently inhibiting the growth of cancer cells bearing BRCA1/2 mutations and inducing potent and specific degradation of PARP1 in various human ca |
|
| DCC4755 | Skf64346 Hydrochloride | Inhibitor of Aβ self-aggregation |
|
| DCC4756 | Skf-80723 Hydrobromide | Dopamine D1 receptor agonist |
|
| DCC4757 | Skf-99101h | Selective, brain penetrant 5-HT(1B/D) receptor agonist |
|
| DCC4758 | Ski-349 | Novel dual-targeted inhibitor of sphingosine kinase and microtubule polymerization |
|
| DCC4759 | Ski-417616 | Potent inhibitor of Dengue viruses (DENV), displaying activities against all four serotypes of DENV, as well as to a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV) |
|
| DCC4760 | S-kkwk | Potent influenza A virus (IAV) entry inhibitor, targeting a conserved region of hemagglutinin |
|
| DCC4761 | sklb023 | Novel inhibitor of NF |
|
| DCC4762 | Sklb028 | Millepachine analog, inhibiting tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin |
|
| DCC4763 | Sklb050 | Biological Active Reagents |
|
| DCC4764 | Sklb-163 | Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK |
|
| DCC4765 | Sklb-329 | Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase |
|
| DCC4766 | Sklb-677 | Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML |
|
| DCC4767 | Sklb70326 | Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells |
|
| DCC4768 | Skog102 | Novel inhibitor of OLIG2 in glioblastoma |
|
| DCC4769 | skp Inhibitor C16 | Specific Inhibitor of Skp2-Mediated p27 Degradation |
|
| DCC4770 | skp Inhibitor C20 | Specific Inhibitor of Skp2-Mediated p27 Degradation |
|
| DCC4771 | Skp2 Inhibitor C2 | First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation |
|
| DCC4772 | Sl-1-73 | Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma |
|
| DCC4773 | Sl-3-19 | Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma |
|
| DCC4774 | Sl-651498 | Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits. |
|
| DCC4775 | Sl910102 | Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19 |
|
| DCC4776 | Slec-8 | Potential synthetic lethal lead, targeting E-cadherin-deficient cells |
|
| DCC4777 | Slk/stk10-in-31 | Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10) |
|
| DCC4778 | Sll-039 | Novel highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283) |
|
| DCC4779 | Slm6071469 | Novel potent SphK2-selective inhibitor (Ki = 89 nM, 73-fold SphK2-selective) with validated in vivo activity |
|
